Zosano Pharma to Host Conference Call on Third Quarter 2018 Financial Results and Provide Operational Update
08 11월 2018 - 6:30AM
Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the
“Company”), a clinical-stage biopharmaceutical company, today
announced that it will host a conference call and webcast to be
held on Wednesday, November 14, 2018 at 4:30PM ET. At this time,
management will discuss results for the third quarter of 2018 and
provide an operational update. The Company will announce its
financial results for this period in a press release to be issued
prior to the call.
To access the live webcast, please visit the Investor Relations
page of the Zosano Pharma website at
http://ir.zosanopharma.com/events.cfm. Alternatively, you may
access the live conference call by dialing (844) 379-5311 (U.S.) or
(209) 905-5963 (international). The conference ID number is
3144819.
A replay will be available on the company's website
approximately three hours after the call and available through
December 14, 2018.
About M207
M207 is Zosano’s proprietary formulation of zolmitriptan
delivered utilizing its proprietary ADAM technology. Zosano's ADAM
technology consists of titanium microprojections (microneedles)
coated with drug, and in the case of M207, its formulation of
zolmitriptan. The drug-coated microneedles penetrate into the
epidermis and dermis, where the drug is dissolved and enters into
the bloodstream. In February 2017, the Company announced
statistically significant results from the ZOTRIP pivotal study,
which demonstrated that the 3.8mg dose of M207 met both co-primary
endpoints, achieving pain freedom and most bothersome symptom
freedom at 2 hours. In November 2017, the Company announced the
initiation of its long-term safety study evaluating M207 and
expects to file a New Drug Application for M207 in the fourth
quarter of 2019.
Forward-Looking Statements
This press release contains forward-looking statements. All
statements other than statements of historical facts contained
herein are forward-looking statements reflecting the current
beliefs and expectations of management made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995, including, but not limited to, statements regarding the
expected timing of a New Drug Application for M207 and other future
events and expectations. Readers are urged to consider statements
that include the words "may," "will," "would," "could," "should,"
"might," "believes," "estimates," "projects," "potential,"
"expects," "plans," "anticipates," "intends," "continues,"
"forecast," "designed," "goal," "approximately" or the negative of
those words or other comparable words to be uncertain and
forward-looking. These statements are subject to risks and
uncertainties that are difficult to predict and actual outcomes may
differ materially. These include, without limitation, risks and
uncertainties associated with the process of discovering,
developing and commercializing products that are safe and effective
for use as human therapeutics, risks and uncertainties relating to
the Company’s dependence on third parties for the development and
commercialization of M207, risks and uncertainties of the
regulatory approval process, risks and uncertainties inherent in
the effort to build a business around such products and other risks
and uncertainties described under the heading "Risk Factors" in the
Company's most recent annual report on Form 10-K filed with the
Securities and Exchange Commission on March 12, 2018. Although
Zosano believes that the expectations reflected in these
forward-looking statements are reasonable, it cannot in any way
guarantee that the future results, level of activity, performance
or events and circumstances reflected in forward-looking statements
will be achieved or occur. Zosano assumes no obligation to update
any forward-looking statements contained in this press release,
whether as a result of any new information, future events, changed
circumstances, or otherwise.
Zosano Contact:Greg KitchenerChief Financial
Officer 510-745-1200
Media Contact:Sara ZelkovicLifeSci Public
Relationssara@lifescipublicrelations.com 646-876-4933
Zosano Pharma (NASDAQ:ZSAN)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Zosano Pharma (NASDAQ:ZSAN)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024